CVS Pharmacy is cutting a multimillion-dollar check to New York after a sweeping investigation found the chain pumped out more insulin than doctors ordered and billed Medicaid for early refills that patients were not supposed to get yet.
Officials say a multistate probe uncovered a long-running practice in which CVS pharmacies routinely over-dispensed insulin and triggered premature refills that padded claims to government health plans. The national settlement totals $36.5 million, with New York’s slice coming in at about $2.26 million for the state Medicaid program. Investigators say the conduct ran from 2010 through 2020 and affected public health programs across the country.
New York Attorney General Letitia James said she joined a bipartisan coalition of 36 other attorneys general and the U.S. Department of Justice to hammer out the deal, according to a press release from the Office of the Attorney General. Her office said more than $25 million will be returned to Medicaid programs nationwide and confirmed that New York’s exact share is $2,257,250.51, which includes restitution to the state.
Federal Case and CVS Admissions
The settlement tracks a separate federal case that had already put CVS under a microscope. The U.S. Attorney’s Office for the Southern District of New York filed a complaint describing how some CVS locations allegedly reported artificially low “days-of-supply” when they dispensed insulin cartons, making it look like patients would run out sooner than they actually would.
That kind of recordkeeping, according to federal prosecutors, could greenlight early refill approvals and generate extra reimbursements from government health programs. In that same matter, CVS “admitted and accepted responsibility for certain conduct” tied to its refilling and billing practices, according to the U.S. Attorney’s Office, which laid out the government’s case in a December 2025 filing.
How the $36.5 Million Deal Gets Split
Under the settlement, CVS agreed to pay $36.5 million to the United States and Medicaid-participating states. Roughly $25.11 million of that is earmarked for state Medicaid programs, with $2,257,250.51 allocated to New York, part of which is specifically labeled as restitution in the state’s paperwork. Local coverage in Brooklyn Eagle detailed the payout breakdown.
The formal settlement paperwork spells out how states must opt in, how the money flows into a national settlement account, and how it is ultimately routed back to state Medicaid coffers, including New York’s. Those mechanics, including the role of the national account, are laid out in the settlement agreement.
How Investigators Say the Overbilling Worked
Prosecutors and investigators describe a fairly simple scheme, dressed up in pharmacy software. CVS locations sometimes dispensed sealed cartons that contained multiple insulin pens, then recorded a smaller number of “days-of-supply” than the insulin actually covered.
Once those low day-counts were in the system, refill logic and auto-refill prompts could kick in early, creating a stream of premature refill opportunities and billable claims. When pharmacy benefit managers and other payors did audits, they flagged chargebacks and tried to claw money back, but investigators say the pattern continued long enough to generate improper reimbursements.
The government’s complaint and related filings walk through how inaccurate entries, software prompts, and refill policies combined to produce early refills and inflated bills. The U.S. Attorney’s Office detailed that sequence in its public filing.
“When big companies defraud Medicaid, hardworking New Yorkers pay the price,” Attorney General James said, calling the settlement a win for both patients and taxpayers, in a statement from the Office of the Attorney General. She said her office will keep going after alleged fraud that drains money from essential health care.
Whistleblowers Helped Blow the Lid Off
This case did not surface by accident. Federal prosecutors intervened in several private whistleblower lawsuits that were initially filed under seal under the False Claims Act’s qui tam provisions. Those insiders described internal pharmacy practices that allegedly understated days-of-supply and generated suspicious refill patterns.
Under federal law, successful whistleblowers can score a share of the money the government recovers. In this case, whistleblower counsel said the relators will receive about 19.5 percent of the overall recovery, according to Vogel, Slade & Goldstein, which represents one of the relators.
A Pattern of Pharmacy Crackdowns
This is not the first time regulators have gone after a major chain over insulin pens. In 2019, Walgreens agreed to pay more than $200 million to resolve similar allegations that it over-dispensed insulin pens and misreported days-of-supply. That case signaled that pharmacy billing and dispensing practices were firmly on law enforcement’s radar. Bloomberg reported on the Walgreens settlement at the time.
Under the new CVS agreement, each state has to sign its own settlement papers within a set opt-in window before the funds move into the shared national account. Portions of New York’s payment are specifically tagged as restitution, and the documents lay out the timing, applicable interest, and the exact process for returning money to state Medicaid programs, as detailed in the settlement agreement.
For New Yorkers on Medicaid who rely on affordable insulin, officials say the settlement is a pointed reminder that how pharmacies bill is not just a back-office issue. The money heading back into Medicaid is expected to support patient care, and both Medicaid investigators and state prosecutors say they will keep watching pharmacy practices to prevent similar hits to the public purse.
